PE97298A1 - Composicion para vacunas - Google Patents
Composicion para vacunasInfo
- Publication number
- PE97298A1 PE97298A1 PE1997000672A PE00067297A PE97298A1 PE 97298 A1 PE97298 A1 PE 97298A1 PE 1997000672 A PE1997000672 A PE 1997000672A PE 00067297 A PE00067297 A PE 00067297A PE 97298 A1 PE97298 A1 PE 97298A1
- Authority
- PE
- Peru
- Prior art keywords
- falciparum
- vivax
- protein
- plasmodium
- adjuvant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
CARACTERIZADA PORQUE COMPRENDE UNA VARIEDAD DE ANTIGENOS DERIVADOS DE PLASMODIUM EN COMBINACION CON UN ADYUVANTE, EN DONDE: LOS ANTIGENOS SE SELECCIONAN DE (a) UNA PROTEINA HIBRIDA, QUE COMPRENDE UNA PORCION TERMINAL-C DE LA PROTEINA DE SUPERFICIE DEL ESPOROZOITO (CS) DEL P. FALCIPARUM, CUATRO O MAS REPETIDORES DE TANDEM DE LA REGION INMUNODOMINANTE Y LA SUPERFICIE ANTIGENA DEL VIRUS DE HEPATITIS B (HBsAg), (b) EL TRAP DE UN AISLADO CLONADO DEL PLASMODIUM FALCIPARUM DE TAILANDIA (T/9/96), (c) LA PROTEINA 16kD, (d) LA MEMBRANA APICA ANTIGENA-1 (AMA-1) DE P. FALCIPARUM o P. VIVAX, (e) LA PROTEINA CIRCUNESPOROZOITA (CSP) DEL P. FALCIPARUM o P. VIVAX, (f) EL MSP-1 DE P. FALCIPARUM o P. VIVAX, (g) OTRAS PROTEINAS DE LA ETAPA EXOERITROCITICA, (h) OPCIONALMENTE, PROTEINAS DE LA ETAPA SANGUINEA; EL ADYUVANTE ES UNA EMULSION DEL TIPO ACEITE EN AGUA QUE COMPRENDE: (a) MPL (LIPIDO MONOFOSFORILO) Y (b) QS21 (FRACCION NO TOXICA PURIFICADA POR HPLC DE UNA SAPONINA OBTENIDA DE LA CORTEZA DEL ARBOL SUDAMERICANO QUILLAJA SAPONARIA MOLINA), EN DONDE DICHO ADYUVANTE TIENE CAPACIDAD ESTIMULANTE DE LA RESPUESTA CELULAR DEL TIPO TH1. ESTA VACUNA CONFIERE INMUNIDAD CONTRA EL PLASMODIUM FALCIPARUM Y/O PLASMODIUM VIVAX, SIENDO UTIL EN LA PREVENCION Y TRATAMIENTO DE LA MALARIA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9616351.4A GB9616351D0 (en) | 1996-08-02 | 1996-08-02 | Vaccine composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE97298A1 true PE97298A1 (es) | 1999-02-14 |
Family
ID=10797980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1997000672A PE97298A1 (es) | 1996-08-02 | 1997-08-01 | Composicion para vacunas |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US20020172692A1 (es) |
| EP (2) | EP1623720A3 (es) |
| JP (1) | JP2000517295A (es) |
| KR (1) | KR20000029747A (es) |
| CN (1) | CN1241639C (es) |
| AP (1) | AP1166A (es) |
| AR (1) | AR008799A1 (es) |
| AT (1) | ATE394119T1 (es) |
| AU (1) | AU706303B2 (es) |
| BG (1) | BG63290B1 (es) |
| BR (1) | BR9710913A (es) |
| CA (1) | CA2262402A1 (es) |
| CO (1) | CO4650186A1 (es) |
| CZ (1) | CZ290826B6 (es) |
| DE (1) | DE69738672D1 (es) |
| DZ (1) | DZ2283A1 (es) |
| EA (1) | EA002167B1 (es) |
| GB (1) | GB9616351D0 (es) |
| ID (1) | ID17860A (es) |
| IL (1) | IL128318A (es) |
| MA (1) | MA24291A1 (es) |
| MY (1) | MY116128A (es) |
| NO (1) | NO319844B1 (es) |
| OA (1) | OA10969A (es) |
| PE (1) | PE97298A1 (es) |
| PL (1) | PL188741B1 (es) |
| SK (1) | SK282438B6 (es) |
| TR (1) | TR199900195T2 (es) |
| UA (1) | UA68336C2 (es) |
| UY (1) | UY24654A1 (es) |
| WO (1) | WO1998005355A1 (es) |
| ZA (1) | ZA976815B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9915204D0 (en) * | 1999-06-29 | 1999-09-01 | Smithkline Beecham Biolog | Vaccine |
| CA2502268A1 (en) | 2002-10-23 | 2004-05-06 | Glaxosmithkline Biologicals S.A. | Methods for vaccinating against malaria |
| CN102030818B (zh) * | 2003-12-01 | 2013-03-27 | 株式会社明治 | 血管紧张素转化酶抑制肽 |
| GB0513421D0 (en) * | 2005-06-30 | 2005-08-03 | Glaxosmithkline Biolog Sa | Vaccines |
| NZ565512A (en) * | 2005-08-02 | 2011-08-26 | Novartis Vaccines & Diagnostic | Reducing interference between oil-containing adjuvants and surfactant-containing antigens |
| AU2007276219B2 (en) * | 2006-07-18 | 2013-10-03 | Glaxosmithkline Biologicals S.A. | Vaccines for malaria |
| GB0614254D0 (en) * | 2006-07-18 | 2006-08-30 | Smithkline Beecham Biolog | Vaccine |
| CN103585624A (zh) | 2006-09-07 | 2014-02-19 | 葛兰素史密丝克莱恩生物有限公司 | 疫苗 |
| UY31285A1 (es) | 2007-08-13 | 2009-03-31 | Vacunas | |
| CN102026657A (zh) * | 2007-12-21 | 2011-04-20 | 葛兰素史密丝克莱恩生物有限公司 | 疟疾疫苗 |
| WO2009080803A1 (en) | 2007-12-24 | 2009-07-02 | Glaxosmithkline Biologicals S.A. | Vaccines for malaria |
| US20120015000A1 (en) * | 2008-06-30 | 2012-01-19 | David Lanar | Malaria vaccine of self-assembling polypeptide nanoparticles |
| EP3351266A1 (en) * | 2009-11-05 | 2018-07-25 | The United States of America as represented by the Secretary of the Navy | Plasmodium falciparum sporozoite and liver stage antigens |
| WO2012041669A1 (en) | 2010-09-27 | 2012-04-05 | Crucell Holland B.V. | Heterologous prime boost vaccination regimen against malaria |
| GB201116248D0 (en) | 2011-09-20 | 2011-11-02 | Glaxosmithkline Biolog Sa | Liposome production using isopropanol |
| US20130122038A1 (en) | 2011-11-14 | 2013-05-16 | The United States Of America As Represented By The Secretary Of The Department | Heterologous prime-boost immunization using measles virus-based vaccines |
| US9169304B2 (en) | 2012-05-01 | 2015-10-27 | Pfenex Inc. | Process for purifying recombinant Plasmodium falciparum circumsporozoite protein |
| CN104338129B (zh) * | 2013-07-26 | 2017-05-24 | 中国科学院上海巴斯德研究所 | 雷帕霉素作为疫苗佐剂的用途及制备方法 |
| JP7136777B2 (ja) | 2016-12-07 | 2022-09-13 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 新規プロセス |
| GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
| FR3066920A1 (fr) | 2017-05-30 | 2018-12-07 | Glaxosmithkline Biologicals S.A. | Nouveaux procedes de fabrication d'un adjuvant |
| MX2020005481A (es) | 2017-12-01 | 2020-12-07 | Glaxosmithkline Biologicals Sa | Purificacion de saponina. |
| WO2020245207A1 (en) | 2019-06-05 | 2020-12-10 | Glaxosmithkline Biologicals Sa | Saponin purification |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3280028D1 (en) * | 1981-05-21 | 1989-12-28 | Wellcome Found | Protozoal antigen |
| PT82282B (pt) * | 1985-03-28 | 1988-02-17 | Univ New York | Processo de preparacao de um conjugado de proteina de suporte-antigeno imunogenico para uso como vacina contra malaria |
| GB8819209D0 (en) * | 1988-08-12 | 1988-09-14 | Research Corp Ltd | Polypeptide & dna encoding same |
| GB9012580D0 (en) * | 1990-06-06 | 1990-07-25 | Univ Nijmegen | Novel protein |
| FR2679776A1 (fr) * | 1991-07-31 | 1993-02-05 | Pasteur Institut | Melange de constituants peptidiques ayant des proprietes vaccinantes contre le paludisme, notamment du a plasmodium falciparum. |
| JP3954643B2 (ja) * | 1991-11-16 | 2007-08-08 | グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム | マラリア原虫由来のＣＳおよびＨＢｓＡＧ間のハイブリッド蛋白質 |
| US6169171B1 (en) * | 1992-02-27 | 2001-01-02 | Smithkline Beecham Biologicals (S.A.) | Hybrid protein between CS from plasmodium and HBSAG |
| EP0761231B1 (en) * | 1992-06-25 | 2000-01-12 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine composition containing adjuvants |
| GB9326253D0 (en) * | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| AUPM368994A0 (en) * | 1994-02-04 | 1994-02-24 | Saramane Pty Ltd | Malaria merozoite antigen subunit vaccine |
| FR2744723A1 (fr) * | 1996-02-14 | 1997-08-14 | Pasteur Institut | Proteine recombinante contenant un fragment c-terminal d'une proteine msp-1 d'un plasmodium infectieux pour l'homme pour la production de vaccins anti-paludiques |
| FR2744724B1 (fr) * | 1996-02-14 | 2002-08-02 | Pasteur Institut | Proteine recombinante contenant un fragment c-terminal de la proteine msp-1 d'un plasmodium infectieux pour l'homme pour la production de vaccins anti-paludiques |
-
1996
- 1996-08-02 GB GBGB9616351.4A patent/GB9616351D0/en active Pending
-
1997
- 1997-07-30 DZ DZ970133A patent/DZ2283A1/fr active
- 1997-07-31 ZA ZA9706815A patent/ZA976815B/xx unknown
- 1997-07-31 SK SK115-99A patent/SK282438B6/sk unknown
- 1997-07-31 MA MA24749A patent/MA24291A1/fr unknown
- 1997-07-31 UA UA99010527A patent/UA68336C2/uk unknown
- 1997-07-31 BR BR9710913A patent/BR9710913A/pt not_active Application Discontinuation
- 1997-07-31 AP APAP/P/1999/001448A patent/AP1166A/en active
- 1997-07-31 EP EP05077131A patent/EP1623720A3/en not_active Withdrawn
- 1997-07-31 CA CA002262402A patent/CA2262402A1/en not_active Abandoned
- 1997-07-31 EA EA199900069A patent/EA002167B1/ru not_active IP Right Cessation
- 1997-07-31 TR TR1999/00195T patent/TR199900195T2/xx unknown
- 1997-07-31 DE DE69738672T patent/DE69738672D1/de not_active Expired - Fee Related
- 1997-07-31 KR KR1019997000855A patent/KR20000029747A/ko not_active Application Discontinuation
- 1997-07-31 CZ CZ1999292A patent/CZ290826B6/cs not_active IP Right Cessation
- 1997-07-31 IL IL12831897A patent/IL128318A/en not_active IP Right Cessation
- 1997-07-31 MY MYPI97003495A patent/MY116128A/en unknown
- 1997-07-31 PL PL97331424A patent/PL188741B1/pl not_active IP Right Cessation
- 1997-07-31 EP EP97940062A patent/EP0957933B1/en not_active Expired - Lifetime
- 1997-07-31 ID IDP972672A patent/ID17860A/id unknown
- 1997-07-31 JP JP10507631A patent/JP2000517295A/ja active Pending
- 1997-07-31 AU AU42040/97A patent/AU706303B2/en not_active Ceased
- 1997-07-31 WO PCT/EP1997/004326 patent/WO1998005355A1/en active IP Right Grant
- 1997-07-31 AT AT97940062T patent/ATE394119T1/de not_active IP Right Cessation
- 1997-07-31 CN CNB971983607A patent/CN1241639C/zh not_active Expired - Fee Related
- 1997-08-01 AR ARP970103502A patent/AR008799A1/es not_active Application Discontinuation
- 1997-08-01 UY UY24654A patent/UY24654A1/es not_active IP Right Cessation
- 1997-08-01 CO CO97044242A patent/CO4650186A1/es unknown
- 1997-08-01 PE PE1997000672A patent/PE97298A1/es not_active Application Discontinuation
-
1999
- 1999-02-01 NO NO19990464A patent/NO319844B1/no unknown
- 1999-02-02 BG BG103141A patent/BG63290B1/bg unknown
- 1999-02-02 OA OA9900022A patent/OA10969A/en unknown
-
2001
- 2001-12-18 US US10/024,860 patent/US20020172692A1/en not_active Abandoned
-
2006
- 2006-08-11 US US11/463,933 patent/US20060292170A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE97298A1 (es) | Composicion para vacunas | |
| RU2356577C9 (ru) | Способы вакцинации против малярии | |
| ES2150493T3 (es) | Adyuvantes para vacunas contra el virus sincitico respiratorio. | |
| MX2007016240A (es) | Vacuna antimalaria. | |
| DK0880588T3 (da) | Rekombinant protein som indeholder et C-terminalt fragment af MSP-1 fra plasmodium | |
| RU2007109608A (ru) | Вакцины, содержащие антиген plasmodium | |
| GB9406492D0 (en) | Malaria peptides | |
| Camacho et al. | TLR5-dependent immunogenicity of a recombinant fusion protein containing an immunodominant epitope of malarial circumsporozoite protein and the FliC flagellin of Salmonella Typhimurium | |
| US20060073171A1 (en) | Vaccine composition against malaria | |
| NZ227943A (en) | An antigen derived from the neck region of the rhoptries of merozoites and vaccine against plasmodium falciparum | |
| ZA888580B (en) | New immunologically active synthetic peptides useful for preparing an antimalarial vaccine | |
| Pinzon-Charry et al. | Malaria vaccines: New hope in old ideas | |
| Hockmeyer et al. | Sporozoite malaria vaccines | |
| Cheong et al. | Immunogenicity of the merozoite surface protein-1 (msp-1) of human plasmodium sp. | |
| Good et al. | T ABILITY OF AN INDIVIDUAL, TO | |
| UY23357A1 (es) | Un antigeno de fases sanguineas de plasmodium falciparum, su preparacion y utilizacion | |
| MX9710523A (es) | Vacunas contra hepatitis c. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |